Autolus Ltd.
Autolus Ltd. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Autolus Ltd..
Autolus Ltd. is a company.
Key people at Autolus Ltd..
Autolus Therapeutics plc (Nasdaq: AUTL) is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, primarily CAR T cell therapies, for cancer and autoimmune diseases.[1][2][3][4][5] It engineers precisely targeted, controlled, and highly active T cells using proprietary modular technologies to recognize cancer cells, overcome their defenses, and eliminate them, aiming to provide life-changing benefits over standard treatments like chemotherapy.[1][2][3][4][5] The company serves patients with hematological malignancies, solid tumors, and autoimmune conditions through a clinical-stage pipeline of five programs across nine indications, supported by in-house manufacturing in Stevenage, UK.[2][3][5] Growth momentum includes rapid expansion since its 2014 spin-out, pivotal programs like obe-cel for relapsed/refractory adult ALL, strategic partnerships, and a focus on commercialization with recent FDA approvals highlighted in company updates.[1][2][3][5]
Autolus was spun out from University College London in 2014, founded on advanced cell programming technology pioneered by Dr. Martin Pule.[2] The idea emerged from Pule's research in T cell therapies, leading to the development of chimeric antigen receptors (CARs) and modular programming to enhance T cell activity, safety, and durability for cancer treatment.[1][2][5] Early traction came from systematic buildup of manufacturing, development, and commercialization capabilities, including a 2018 long-term supply agreement with Miltenyi Biotec and the opening of a purpose-built facility in Stevenage, UK.[3] The company went public via a Nasdaq IPO of American Depositary Shares in 2018, marking a pivotal shift to a fully integrated CAR T player with a broadening pipeline into autoimmune diseases.[2][3]
Autolus rides the wave of cell therapy innovation, particularly CAR T expansion beyond blood cancers into solid tumors and autoimmune diseases, addressing unmet needs where traditional therapies fail.[1][2][3][5] Timing aligns with maturing immunotherapy regulations, like recent FDA approvals, and growing demand for curative options in oncology amid rising cancer incidence.[1][3] Market forces favoring it include modular tech enabling faster iteration, cost-effective manufacturing reducing scalability barriers, and a shift toward outpatient-accessible therapies.[3][5] It influences the ecosystem by advancing "best-in-class" standards, partnering with specialists, and pushing boundaries in immune system harnessing for serious diseases.[2][4][8]
Autolus is poised for commercialization milestones, with obe-cel leading in adult ALL and pipeline expansion into additional indications, supported by manufacturing ramps and regional hubs.[2][3][5] Trends like autoimmune applications and solid tumor breakthroughs will shape its path, potentially establishing it as a global CAR T leader amid competition from big pharma.[1][2] Influence may evolve through broader accessibility, more partnerships, and tech licensing, delivering transformative outcomes that redefine cancer care—echoing its founding mission to revolutionize treatment with precisely targeted therapies.[1][2]
Key people at Autolus Ltd..
